PhRMA names new SVP federal advocacy
WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday announced the appointment of Charles “Chuck” Clapton to the position of SVP federal advocacy, effective March 17, 2014.
In this capacity, Clapton will be responsible for leading PhRMA’s federal government affairs initiatives and advancing its legislative agenda, working with stakeholders to develop and advocate for health policies that foster innovation and ensure patient access to new medicines in the United States and around the world.
He will report to Chip Davis, EVP advocacy and member relations.
“Chuck is a dynamic advocate and an expert on the policy issues facing the biopharmaceutical sector and the patients we serve,” said John Castellani, president and CEO of PhRMA. “He will make important contributions to our work with policymakers on promoting research and innovation and making progress for patients.”
Most recently, Clapton worked as a partner at the international law firm HoganLovells, where he represented healthcare clients on legislative and regulatory matters. Prior to joining HoganLovells, Clapton worked for 17 years on Capitol Hill, where he held several leadership positions on the House Energy & Commerce Committee, Ways & Means Committee, Office of the Speaker and the Senate Health, Education, Labor and Pensions Committee.
“Chuck’s experience, reputation and results-oriented focus during his distinguished career on Capitol Hill will be tremendous assets to PhRMA and its members as he leads our federal advocacy efforts,” Davis said.
During his time with the House and Senate, Clapton worked on reimbursement and coverage initiatives, including the Medicare Modernization Act that created the highly successful Medicare Part D drug program. In addition, he has extensive experience with policy issues related to Food and Drug Administration review and approval of new medicines, the distribution and use of non-FDA approved drugs, and other critical patient safety matters.
Clapton earned his J.D. from the Catholic University, Columbus School of Law and B.A. from Boston College.